Induction Healthcare Group PLC
("Induction", the "Company", or the "Group")
Update on publication of Audited Final Results
Induction (AIM: INHC), a leading digital health platform driving transformation of healthcare systems worldwide, announces that its audited final results for the year ended 31 March 2022 will now be released on or before Monday 28 November 2022. This is as a result of staff shortages at the Company's auditor and following the unexpected bereavement of a family member of one of the Company's Board.
There is no change to the financial performance and, as previously reported on 22 September, results for FY22 are expected to be in-line with guidance.
Induction will announce its interim results for the six months ended 30 September 2022 shortly after the publication of the 2022 audited results.
During November, the Board expect to issue a trading update on the six-month period to 30 September 2022.
ENQUIRIES
| Induction James Balmain, Chief Executive Officer Guy Mitchell, Chief Financial Officer | Via Walbrook PR Ltd: induction@walbrookpr.com |
| |
|
| Singer Capital Markets (Nominated Adviser and Broker) | +44 (0)20 7496 3000 |
| Philip Davies / Kailey Aliyar |
|
| |
|
| Walbrook PR Ltd | induction@walbrookpr.com |
| Alice Woodings | Mob: +44 (0)7407 804 654 |
About Induction - www.inductionhealthcare.com
Induction (AIM: INHC) Induction delivers a suite of software solutions through a single integrated platform that transforms care delivery. Our system-wide applications help healthcare providers and administrators to deliver care at any stage remotely as well as face-to-face - giving the communities they serve greater flexibility, control and ease of access. Purpose-built for integration with leading Electronic Medical Record (EMR) platforms, our products offer immediate stand-alone value that becomes even greater when integrated with pre-existing systems.
Used at scale by national and regional healthcare systems, as well non-health government services, our applications are relied upon by hundreds of thousands of clinicians and millions of patients across almost every hospital in the British Isles.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
